Skip to main content
Erschienen in: Rheumatology International 3/2010

01.01.2010 | Short Communication

Scoring evaluation for histopathological features of synovium in patients with rheumatoid arthritis during anti-tumor necrosis factor therapy

verfasst von: Hajime Yamanaka, Ken-ichiro Goto, Kazutoshi Miyamoto

Erschienen in: Rheumatology International | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

The present study was performed to evaluate the synovium in patients with rheumatoid arthritis (RA) treated with anti-tumor necrosis factor α agents (anti-TNFα). Synovial tissue specimens were obtained during total knee arthroplasty (TKA) from 42 RA patients (12 men, 30 women). Twenty-one RA patients were given anti-TNFα agents (infliximab, n = 12; etanercept, n = 9), while the remaining 21 RA patients were given no such agents. The histopathological findings were compared between specimens from these groups using the histological scoring system reported by Rooney, which consists of six items: degree of synovial hyperplasia, fibrosis, number of blood vessels, perivascular lymphocyte infiltration, focal aggregates of lymphocytes, and diffuse infiltrates of lymphocytes. Clinical laboratory data including C-reactive protein (CRP), matrix metalloproteinase-3 (MMP-3), and disease activity scores including a 28-joint count (DAS28), disease duration, methotrexate (MTX) dose, and glucocorticoid dose were also assessed before surgery. There were no significant differences in total score between anti-TNFα and no anti-TNFα groups. However, significant differences were observed in scores of synoviocyte hyperplasia and perivascular infiltrates of lymphocytes between the groups. These results suggested that these agents have a suppressive effect on cell proliferation in the lining layer and on perivascular lymphocyte infiltration. However, further studies are necessary to elucidate the mechanisms of these effects.
Literatur
1.
Zurück zum Zitat Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AL, Bacon PA (1984) Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 43:8–17CrossRefPubMed Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AL, Bacon PA (1984) Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 43:8–17CrossRefPubMed
2.
Zurück zum Zitat Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602CrossRefPubMed Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602CrossRefPubMed
3.
Zurück zum Zitat van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J et al (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiolographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54:1063–1074CrossRefPubMed van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J et al (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiolographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54:1063–1074CrossRefPubMed
4.
Zurück zum Zitat Hyrich K, Lunt M, Watson K, Symmons D, Silman A (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56:13–20CrossRefPubMed Hyrich K, Lunt M, Watson K, Symmons D, Silman A (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56:13–20CrossRefPubMed
5.
Zurück zum Zitat Yamanaka H, Tanaka Y, Sekiguchi E, Inoue E, Saito K, Kameda H, Iikuni N et al (2007) Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 17:28–32CrossRefPubMed Yamanaka H, Tanaka Y, Sekiguchi E, Inoue E, Saito K, Kameda H, Iikuni N et al (2007) Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 17:28–32CrossRefPubMed
6.
Zurück zum Zitat Seki E, Matsushita I, Sugiyama E, Taki H, Shinoda K, Hounoki H et al (2009) Radiographic progression in weight-bearing joints of patients with rheumatoid arthritis after TNF-blocking therapies. Clin Rheumatol 28:453–460CrossRefPubMed Seki E, Matsushita I, Sugiyama E, Taki H, Shinoda K, Hounoki H et al (2009) Radiographic progression in weight-bearing joints of patients with rheumatoid arthritis after TNF-blocking therapies. Clin Rheumatol 28:453–460CrossRefPubMed
7.
Zurück zum Zitat Ulfgren AK, Lindblad S, Klareskog L, Andersson J, Andersson U (1995) Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 54:654–661CrossRefPubMed Ulfgren AK, Lindblad S, Klareskog L, Andersson J, Andersson U (1995) Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 54:654–661CrossRefPubMed
8.
Zurück zum Zitat van der Pouw Kraan TC, van der Gaalen FA, Huizinga TW, Pieterman E, Breedveld FC, verweij CL (2003) Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun 4:187–196CrossRefPubMed van der Pouw Kraan TC, van der Gaalen FA, Huizinga TW, Pieterman E, Breedveld FC, verweij CL (2003) Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun 4:187–196CrossRefPubMed
9.
Zurück zum Zitat Fassbender HG (1975) Rheumatoid arthritis. In: Fassbender HG (ed) Pathology of rheumatic disease. Springer, Berlin, pp 79–210 Fassbender HG (1975) Rheumatoid arthritis. In: Fassbender HG (ed) Pathology of rheumatic disease. Springer, Berlin, pp 79–210
10.
Zurück zum Zitat Gardner DL (1986) Pathology of rheumatoid arthritis. In: Scott JT (ed) Copeman’s textbook of the rheumatic disease, vol 2, 6th edn. Churchill Livingstone, New York, pp 604–615 Gardner DL (1986) Pathology of rheumatoid arthritis. In: Scott JT (ed) Copeman’s textbook of the rheumatic disease, vol 2, 6th edn. Churchill Livingstone, New York, pp 604–615
11.
Zurück zum Zitat Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMed
12.
Zurück zum Zitat Rooney M, Condrell D, Quinlan W, Daly L, Whelan A, Feighery C et al (1988) Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 31:956–963CrossRefPubMed Rooney M, Condrell D, Quinlan W, Daly L, Whelan A, Feighery C et al (1988) Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 31:956–963CrossRefPubMed
13.
Zurück zum Zitat Ernestam S, af Klint E, Catrina AI, Sundberg E, Engstrom M, Klareskog L et al (2006) Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumor necrosis factor. Arthritis Res Ther 8:R18CrossRefPubMed Ernestam S, af Klint E, Catrina AI, Sundberg E, Engstrom M, Klareskog L et al (2006) Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumor necrosis factor. Arthritis Res Ther 8:R18CrossRefPubMed
14.
Zurück zum Zitat Catrina AI, Trollmo C, af Klint E et al (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extend report. Arthritis Rheum 52:61–72CrossRefPubMed Catrina AI, Trollmo C, af Klint E et al (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extend report. Arthritis Rheum 52:61–72CrossRefPubMed
15.
Zurück zum Zitat Smeets TJM, Kraan M, van Loon ME, Tak PP (2003) Tumornecrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 48:2155–2162CrossRefPubMed Smeets TJM, Kraan M, van Loon ME, Tak PP (2003) Tumornecrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 48:2155–2162CrossRefPubMed
16.
Zurück zum Zitat Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM et al (1996) Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 39:1077–1081CrossRefPubMed Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM et al (1996) Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 39:1077–1081CrossRefPubMed
17.
Zurück zum Zitat Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L et al (2002) Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloprotainease (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 41:484–489CrossRefPubMed Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L et al (2002) Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloprotainease (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 41:484–489CrossRefPubMed
18.
Zurück zum Zitat Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys EM, Keyser F (2005) Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodeling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 64:529–536CrossRefPubMed Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys EM, Keyser F (2005) Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodeling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 64:529–536CrossRefPubMed
19.
Zurück zum Zitat Nakazawa M, Aratani S, Hatta M, Araya N, Daitoku H, Kawahara K et al (2002) TNF alpha induces acethylation of p53 but attenuates its transcriptional activation in rheumatoid synoviocytes. Int J Mol Med 10:269–275PubMed Nakazawa M, Aratani S, Hatta M, Araya N, Daitoku H, Kawahara K et al (2002) TNF alpha induces acethylation of p53 but attenuates its transcriptional activation in rheumatoid synoviocytes. Int J Mol Med 10:269–275PubMed
20.
Zurück zum Zitat Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R et al (1999) Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum 43:38–47CrossRef Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R et al (1999) Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum 43:38–47CrossRef
21.
Zurück zum Zitat Mielants H, Veys EM, Goemaere S, Goethals K, Cuvelier C, DeVos M (1991) Gut inflammation in the spondyloarthropathies: clinical, radiogic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol 18:1542–1551PubMed Mielants H, Veys EM, Goemaere S, Goethals K, Cuvelier C, DeVos M (1991) Gut inflammation in the spondyloarthropathies: clinical, radiogic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol 18:1542–1551PubMed
Metadaten
Titel
Scoring evaluation for histopathological features of synovium in patients with rheumatoid arthritis during anti-tumor necrosis factor therapy
verfasst von
Hajime Yamanaka
Ken-ichiro Goto
Kazutoshi Miyamoto
Publikationsdatum
01.01.2010
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 3/2010
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1158-2

Weitere Artikel der Ausgabe 3/2010

Rheumatology International 3/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.